Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
MedMen Enterprises Inc. (OTCQX:MMNFF) revealed Tuesday that it has secured $100 million in financing via a private sale of its units in a deal led by Serruya Private Equity.
At the same time, the company disclosed that Tilray, Inc. (NASDAQ:TLRY) acquired the majority of MedMen’s outstanding senior secured convertible notes that were originally held by certain funds affiliated with Gotham Green Partners LLC (GGP) and others.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Analyst
Cantor Fitzgerald analyst Pablo Zuanic upgraded his rating on MedMen’s stock from Underweight to Neutral and established a price target of $0.30.
The Thesis
Tilray is investing around $118 million in MedMen in order to acquire some 21% contingent stake, based on which it seems that 100% MedMen equity has a value of $561 million, compared to its current market cap of $220 million, explained the analyst.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Zuanic further noted that this deal will not likely double MedMen's valuation because, as seen with other companies such as Acreage Holdings (OTCQX:ACRDF), “stocks with equity investments/valuations contingent on the federal permissibility of cannabis tend to trade at steep discounts to their contingent offer prices.”
Nevertheless, with momentum changing for the company because of recent milestones, Cantor decided to rate the stock Neutral.
“On fully diluted pro-forma numbers, we calculate MedMen trades at 3.4x FactSet consensus CY22E sales compared with 3.1x for the US MSO average,” Zuanic said.
In conclusion, the analyst stressed that MedMen's premium should “stick” thanks to the new deal with Tilray.
The Price Action
MedMen’s shares were trading 1.49% higher at $0.267 per share at the time of writing Wednesday morning.
Photo: Courtesy of davide ragusa on Unsplash
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.